RSS feed

Publications by Hilde Almåsbak

8 publications found

Original articles

Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, Almåsbak H, Bajor M, Clement D, Brandt L, Önfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ (2018)
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Cancer Immunol Res, 6 (4), 467-480
DOI 10.1158/2326-6066.CIR-17-0207, PubMed 29459477

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Oncoimmunology, 6 (4), e1302631
DOI 10.1080/2162402X.2017.1302631, PubMed 28507809

Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098

Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM (2010)
Transiently redirected T cells for adoptive transfer
Cytotherapy, 13 (5), 629-40
DOI 10.3109/14653249.2010.542461, PubMed 21174490

Almåsbak H, Lundby M, Rasmussen AM (2010)
Non-MHC-dependent redirected T cells against tumor cells
Methods Mol Biol, 629, 453-93
DOI 10.1007/978-1-60761-657-3_28, PubMed 20387166

Paus E, Almåsbak H, Børmer OP, Warren DJ (2003)
A single-chain-Fv-based immunofluorometric assay specific for the CEA variant NCA-2
J Immunol Methods, 283 (1-2), 125-39
DOI 10.1016/j.jim.2003.08.018, PubMed 14659905

Review articles

Almåsbak H, Aarvak T, Vemuri MC (2016)
CAR T Cell Therapy: A Game Changer in Cancer Treatment
J Immunol Res, 2016, 5474602
DOI 10.1155/2016/5474602, PubMed 27298832

Theses

Almåsbak H (2004)
A single-chain-Fv-based immunofluorometric assay specificfor the CEA variant NCA-2
H. Almåsbak, Oslo, 121, 17 s.
BIBSYS 041297598